🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002535Source: DataRank Database

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis is a research paper published in Journal for ImmunoTherapy of Cancer (2021). On theSindex it has a DataRank of 0.520. It has been cited 31 times.

N/A

0.520DataRank · unranked

Scored on demand from live citation data

Open Access31 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (38 grants)OA: goldTopics (45)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.520

From this paper's citation signal

Citation Network Contribution

0

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (21)

Ni Kang,Sandra J. Lee ORCID,F. Stephen Hodi ORCID,Gary I. Cohen ORCID,Omid Hamid ORCID

Live enrichment

PubMed:33963015 PMC:PMC8108687

National Cancer Institute of the National Institutes of Health

Grant: U10180794

National Cancer Institute of the National Institutes of Health

Grant: U10CA180820

National Cancer Institute of the National Institutes of Health

Grant: U10CA180821

National Cancer Institute of the National Institutes of Health

Grant: U10CA180863

National Cancer Institute of the National Institutes of Health

Grant: U10CA180888

National Cancer Institute of the National Institutes of Health

Grant: UG1CA189859

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233163

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233180

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233184

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233196

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233234

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233237

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233270

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233320

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233331

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233337

National Cancer Institute of the National Institutes of Health

Grant: UG1CA233373

Canadian Cancer Society

Grant: 704970

NCI NIH HHS

Grant: U10 CA180794

NCI NIH HHS

Grant: UG1 CA233277

NCATS NIH HHS

Grant: UL1 TR001863

National Institutes of Health

Grant: 3U10CA180820-02S3

ECOG-ACRIN Operations Center

National Institutes of Health

Grant: 5UG1CA233320-02

Northwestern University Lead Academic Participating Site

National Institutes of Health

Grant: 3U10CA180888-03S1

SWOG Network Group Operations Center of the NCTN

National Institutes of Health

Grant: 3UG1CA233163-06S1

National Clinical Trials Network (NCTN) - Lead Academic Participating Site (LAPS)

National Institutes of Health

Grant: 5UG1CA233180-02

NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

National Institutes of Health

Grant: 5U10CA180863-08

Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network

National Institutes of Health

Grant: 1UG1CA233184-01

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center

National Institutes of Health

Grant: 3UG1CA233337-06S1

Yale Cancer Center NCTN LAPS

National Institutes of Health

Grant: 5UG1CA233331-03

OSU as a Network Lead Academic Participating Site for the NCI NCTN

National Institutes of Health

Grant: 5UG1CA233234-06

Case Comprehensive Cancer Center NCTN Lead Academic Participating Site

National Institutes of Health

Grant: 5UG1CA233270-02

Vanderbilt Network Lead Academic Participating Site for the NCTN

National Institutes of Health

Grant: 1UG1CA233373-01

UNC Lead Academic Participating Site

National Institutes of Health

Grant: 5UG1CA189859-03

Minority-Based Community Oncology Research Program

National Institutes of Health

Grant: 3U10CA180821-02S2

Alliance for Clinical Trials in Oncology Operations Center

National Institutes of Health

Grant: 5UG1CA233196-03

Johns Hopkins University NCTN Lead Academic Site Program

ECOG-ACRIN Cancer Research Group

Bristol-Myers Squibb

goldLicense: cc-by-nc

publisherhttps://jitc.bmj.com/content/jitc/9/5/e002535.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2021-002535

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8108687

repositoryhttps://doaj.org/article/6f596cfb2e7048f7b2e60a6a21991735

Europe_PMChttps://europepmc.org/articles/PMC8108687

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansMelanomaSkin NeoplasmsImmunosuppressive AgentsAdjuvants, ImmunologicTreatment OutcomeRisk AssessmentRisk FactorsTime FactorsAdolescentAdultAgedAged, 80 and overMiddle AgedFemaleMaleYoung AdultDrug-Related Side Effects and Adverse ReactionsIpilimumabImmune Checkpoint Inhibitors

Keywords

MelanomaAdultMaleSkin NeoplasmsTime FactorsAdolescentDrug-Related Side Effects and Adverse ReactionsRisk AssessmentYoung AdultAdjuvants, ImmunologicRisk FactorsHumansImmune Checkpoint InhibitorsRC254-282AgedClinical/Translational Cancer ImmunotherapyAged, 80 and overNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle AgedIpilimumabTreatment OutcomeFemaleImmunosuppressive Agents

Sustainable Development Goals

SDG 3: 3. Good health

Related Papers (9)

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

N/A

1.3DataRank · unranked

Science(2018)

co-cited

10.1126/science.aan4236

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

N/A

1.2DataRank · unranked

Science(2018)

co-cited

10.1126/science.aao3290

Induction and transcriptional regulation of the co-inhibitory gene module in T cells

N/A

0.918DataRank · unranked

Nature(2018)

co-cited

10.1038/s41586-018-0206-z

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆

Annals of Oncology(2020)

co-cited

10.1016/j.annonc.2020.11.005

Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation

N/A

0.771DataRank · unranked

Communications Biology(2020)

co-cited

10.1038/s42003-020-0845-0

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

N/A

0.910DataRank · unranked

Nature Medicine(2021)

co-cited

10.1038/s41591-021-01406-6

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical Cancer Research(2021)

co-cited

10.1158/1078-0432.ccr-21-0557

Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer

Genome Medicine(2021)

co-cited

10.1186/s13073-021-00923-w

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

N/A

1.3DataRank · unranked

New England Journal of Medicine(2015)

co-cited

10.1056/nejmoa1504030